Replies to post #220062 on Avid Bioservices Inc (CDMO)

[biopharm]

Harold Dvorak : Peregrine Pharmaceuticals KOL : Cancer starts with Inflammation : Part II

...chronic inflammation fuels cancer.

---------------------------------------------------

The Cancer Journal

July/August 2015 - Volume 21 - Issue 4
pp: 235-356

Part I: Tumor Vasculature as a Target: Angiogenesis and Antiangiogenesis


Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy

Dvorak, Harold F.

http://journals.lww.com/journalppo/pages/currenttoc.aspx

--------------------------------


Cancer Journal:
July/August 2015 - Volume 21 - Issue 4 - p 237–243
doi: 10.1097/PPO.0000000000000124
Reviews: Part I: Tumor Vasculature as a Target: Angiogenesis and Antiangiogenesis

Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy

Dvorak, Harold F. MD


Author Information

From the Center for Vascular Biology Research and the Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

This work was supported by National Institutes of Health grants P01 CA92644 and R01 CA142262 and by a contract from the National Foundation for Cancer Research.

The author has disclosed that he has no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Reprints: Harold F. Dvorak, MD, Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, RN227C Boston, MA 02215. E-mail: [e-mail].

Abstract

Abstract: Solid tumors generally require a vascularized connective tissue stroma if they are to grow beyond minimal size. They generate that stroma in part by secreting vascular endothelial growth factor (VEGF), a potent vascular permeability and angiogenic factor. Increased vascular permeability leads to deposition of a provisional fibrin stroma, which supports tumor, connective tissue, and inflammatory cell migration and plays an active role in the formation of mature vascularized stroma. Vascular endothelial growth factor–induced tumor blood vessels are heterogeneous, of at least 6 distinct types, and develop linearly over time. They include both angiogenic (mother vessels, glomeruloid microvascular proliferations, vascular malformations, capillaries) and arteriovenogenic (feeding arteries, draining veins) blood vessels. Attacking the tumor vasculature with drugs that target VEGF or its receptors (VEGFR) has come into vogue but has been less effective than had been hope for. One reason for this is that anti-VEGF/VEGFR therapy attacks only a subset of tumor blood vessels, the earliest to form. New targets on late-forming blood vessels such as feeding arteries would be useful in helping antivascular cancer therapy fulfill its promise.

http://journals.lww.com/journalppo/Fulltext/2015/07000/Tumor_Stroma,_Tumor_Blood_Vessels,_and.2.aspx